This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Risbridger, G. P. Articles by Robertson, D. M. Search for Related Content PubMed PubMed Citation Articles by Risbridger, G. P. Articles by Robertson, D. M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Cancer

Activins and Inhibins in Endocrine and Other Tumors

Centre for Urological Research, Institute of Reproduction and Development, Monash University (G.P.R., J.F.S.), Melbourne, Prince Henry’s Institute of Medical Research (D.M.R.), Clayton, Victoria 3168, Australia

Correspondence: Address all correspondence and requests for reprints to: Dr. Gail P. Risbridger, Associate Professor, Director, Center for Urological Research, Monash Institute of Reproduction and Development, Monash Medical Center, 246 Clayton Road, Clayton, Victoria 3168, Australia. E-mail: gail.risbridger{at}med.monash.edu.au

Inhibin and activin are members of the TGFß superfamily of growth and differentiation factors. They were first identified as gonadal-derived regulators of pituitary FSH and were subsequently assigned multiple actions in a wide range of tissues. More recently, the inhibin subunit was considered as a tumor suppressor based on functional studies employing transgenic mouse models. This review evaluates the functional and molecular evidence that the inhibin subunit is a tumor suppressor in endocrine cancers. The evaluation highlights the discrepant results from the human and mouse studies, as well as the differences between endocrine tumor types. In addition, we examine the evidence that the activin-signaling pathway is tumor suppressive and identify organ-specific differences in the actions and putative roles of this pathway in endocrine tumors. In summary, there is a considerable body of evidence to support the role of inhibins and activins in endocrine-related tumors. Future studies will define the mechanisms by which inhibins and activins contribute to the process of initiation, promotion, or progression of endocrine-related cancers.

This article has been cited by other articles:

				R. V. Korupolu, U. Muenster, J. D. Read, W. Vale, and W. H. Fischer Activin A/Bone Morphogenetic Protein (BMP) Chimeras Exhibit BMP-like Activity and Antagonize Activin and Myostatin J. Biol. Chem., February 15, 2008; 283(7): 3782 - 3790. [Abstract] [Full Text] [PDF]

				J. L. Kipp, S. M. Kilen, T. K. Woodruff, and K. E. Mayo Activin Regulates Estrogen Receptor Gene Expression in the Mouse Ovary J. Biol. Chem., December 14, 2007; 282(50): 36755 - 36765. [Abstract] [Full Text] [PDF]

				Q. Li, J. M. Graff, A. E. O'Connor, K. L. Loveland, and M. M. Matzuk SMAD3 Regulates Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2007; 21(10): 2472 - 2486. [Abstract] [Full Text] [PDF]

				Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683. [Abstract] [Full Text] [PDF]

				L. M Bilezikjian, A. L Blount, C. J Donaldson, and W. W Vale Pituitary actions of ligands of the TGF-{beta} family: activins and inhibins. Reproduction, August 1, 2006; 132(2): 207 - 215. [Abstract] [Full Text] [PDF]

				S. E. Matsuo, S. G. Leoni, A. Colquhoun, and E. T. Kimura Transforming growth factor-{beta}1 and activin A generate antiproliferative signaling in thyroid cancer cells. J. Endocrinol., July 1, 2006; 190(1): 141 - 150. [Abstract] [Full Text] [PDF]

				Y.-G. Chen, Q. Wang, S.-L. Lin, C. D. Chang, J. Chung, and S.-Y. Ying Activin Signaling and Its Role in Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis. Experimental Biology and Medicine, May 1, 2006; 231(5): 534 - 544. [Abstract] [Full Text] [PDF]

				H. Lefevre, C. Bouvattier, N. Lahlou, C. Adamsbaum, P. Bougneres, and J.-C. Carel Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor Eur. J. Endocrinol., February 1, 2006; 154(2): 221 - 227. [Abstract] [Full Text] [PDF]

				M. Bielinska, S. Kiiveri, H. Parviainen, S. Mannisto, M. Heikinheimo, and D. B. Wilson Gonadectomy-induced Adrenocortical Neoplasia in the Domestic Ferret (Mustela putorius furo) and Laboratory Mouse. Vet. Pathol., February 1, 2006; 43(2): 97 - 117. [Abstract] [Full Text] [PDF]

				U. Muenster, C. A. Harrison, C. Donaldson, W. Vale, and W. H. Fischer An Activin-A/C Chimera Exhibits Activin and Myostatin Antagonistic Properties J. Biol. Chem., November 4, 2005; 280(44): 36626 - 36632. [Abstract] [Full Text] [PDF]

				L. Cobellis, F. M. Reis, S. Luisi, S. Danero, L. Pirtoli, G. Scambia, and F. Petraglia High Concentrations of Activin A in the Peritoneal Fluid of Women With Epithelial Ovarian Cancer Reproductive Sciences, May 1, 2004; 11(4): 203 - 206. [Abstract] [PDF]

				C A Longui, S H V Lemos-Marini, B Figueiredo, B B Mendonca, M Castro, R Liberatore Jr, C Watanabe, C L P Lancellotti, M N Rocha, M B Melo, et al. Inhibin {alpha}-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers J. Med. Genet., May 1, 2004; 41(5): 354 - 359. [Abstract] [Full Text] [PDF]

				S. La Rosa, S. Uccella, S. Marchet, C. Capella, and R. V. Lloyd Localization of Inhibins and Activins in Normal Endocrine Cells and Endocrine Tumors of the Gut and Pancreas: an Immunohistochemical and In Situ Hybridization Study J. Histochem. Cytochem., February 1, 2004; 52(2): 217 - 225. [Abstract] [Full Text] [PDF]

				K. H. Burns, J. E. Agno, L. Chen, B. Haupt, S. C. Ogbonna, K. S. Korach, and M. M. Matzuk Sexually Dimorphic Roles of Steroid Hormone Receptor Signaling in Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2003; 17(10): 2039 - 2052. [Abstract] [Full Text] [PDF]

				J. S. Jeruss, C. D. Sturgis, A. W. Rademaker, and T. K. Woodruff Down-Regulation of Activin, Activin Receptors, and Smads in High-Grade Breast Cancer Cancer Res., July 1, 2003; 63(13): 3783 - 3790. [Abstract] [Full Text] [PDF]

				A. Krishnan, C. Murdock, J. Allard, M. Cisar, E. Reid, L. Nieman, and J. Segars Pseudo-isolated FSH deficiency caused by an inhibin B-secreting granulosa cell tumour: Case report Hum. Reprod., March 1, 2003; 18(3): 502 - 505. [Abstract] [Full Text] [PDF]

				D. C. Danila, X. Zhang, Y. Zhou, J. N. S. Haidar, and A. Klibanski Overexpression of Wild-Type Activin Receptor Alk4-1 Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4741 - 4746. [Abstract] [Full Text] [PDF]

				J. F. Schmitt, D. S. Millar, J. S. Pedersen, S. L. Clark, D. J. Venter, M. Frydenberg, P. L. Molloy, and G. P. Risbridger Hypermethylation of the Inhibin {alpha}-Subunit Gene in Prostate Carcinoma Mol. Endocrinol., February 1, 2002; 16(2): 213 - 220. [Abstract] [Full Text] [PDF]